“When the data underlying a study are not disclosed and properly peer-reviewed, the integrity of the findings should be questioned and downplayed within public debate.”
Innovation is the foundation of America’s ability to compete in the global economy, and the cornerstone of America’s foundation is the United States patent system. This is especially true when it comes to America’s leadership in the life sciences. But Washington argues for a political narrative-driven proposal that limits the availability of patents and fails to consider innovation and its impact on American competitiveness.
Our Founding Fathers inherently understood that entrepreneurship was deep within the fabric of this nation and that we needed a system to unlock that talent. The patent system has evolved with the times and continues to set global standards for supporting inventors of all kinds. Decisions by George Washington, Thomas Jefferson and others continue to provide the legal certainty investors need to support research and development.
In the context of this discussion, the risks and potential consequences of weakening patent rights need to be considered. The question is easy. What does the United States and its citizens lose if we do not maintain a robust and credible patent system?
No patent, no investment
The politically compelling narrative promoted by activists that ignoring patents could produce drugs at a lower cost has received a great deal of attention. Conveniently ignored by these activists is the undermining of the patent system, which dries up private sector investment and provides long-term care, treatment, and long-term suffering for people with life-threatening illnesses. It drives up costs. Many people are denied hope of a cure or life-sustaining treatment.
Strong patent rights provide a means to fund innovators and invest in medical research and development. In addition, patents provide inventors with exclusive rights to use their products for a limited period of time, allowing them to recoup their investment costs in the short term once the product is on the market. Within the context of these property rights, and in exchange for the period of exclusivity they confer, the general public benefits from the knowledge of inventors and uses them as building blocks for future advances that will benefit society. may use the intellectual property of
This legal certainty is critical to the viability of the decades-long, multi-billion dollar medical innovation process. Without this certainty, potential competitors are free to wait and benefit from other research investments, ultimately discouraging new research. , a credible patent system is fundamental to the industry’s success.
The U.S. government is currently considering proposals that could weaken patent rights and stifle innovation in medicine and other areas. Misguided efforts to limit continued innovation under the guise of “robust and credible” patent rights; so-called collaboration efforts that place an undue burden on life sciences innovators; and weaponization of the Bayh-Dole Act against universities and start-ups. There is a blatant call to change. Businesses, bad suggestions are getting attention. The activists who have pushed these proposals use politically driven narratives that ignore facts and potentially harmful consequences for patients and consumers.
Stop relying on flawed data
For example, activists claim that they made multiple subtle changes to drugs to create what is commonly referred to as a “patent thicket” that allows life sciences innovators to maintain ownership and make drugs more expensive. accused of maintaining Those who claim to undermine patent rights have repeatedly cited I-MAK’s “Over Patent, Over Price” report as evidence in support of these accusations. But the report falsely claims that the average innovative drug is covered by dozens of worthless patents that unduly extend the term of exclusivity. Despite its inaccurate use and flawed methodology, the report has been embraced by those seeking to undermine patent rights. citing a lack of evidence to support exaggerated and politically motivated claims.
Senator Tom Tillis (R-North Carolina), a ranking member of the Senate Judiciary Committee Subcommittee on Intellectual Property, expressed concern over unsubstantiated data provided by I-MAK, which policymakers relied on. expressed. He requested that relevant government agencies conduct an independent and objective assessment of the data and report on its factual accuracy. Additionally, he called on advocacy groups promoting the data to disclose its evidence, methodology, and datasets. However, the organization refused to provide the requested information. Senator Tillis’ actions highlight the importance of this issue and the need for reliable and transparent data in policy making.
When the underlying data of a study cannot be disclosed and properly peer reviewed, the integrity of the findings should be questioned and downplayed within public debate. This is especially true when research claims contradict accepted empirical research and documented medical breakthroughs. Reliable and transparent data is essential for making informed policy decisions.
Examples of practical patents
Research shows that countries with strong patent rights have more robust and innovative life science sectors. They are experiencing higher medical innovation outcomes, better access to new drugs, and increased clinical trial activity. This evidence highlights the importance of strong patent rights in driving life sciences innovation and highlights the direct link between a strong U.S. patent system and global leadership in life sciences doing.
Patent data shows that the current system drives patient, growth and access. Despite criticism from those who focus on “evergreening” and “patent bloat,” life sciences companies are seeking multiple drug and technology portfolios to ensure access to cumulative and incremental innovation. I am trying to obtain a patent for Various patents cover important aspects of the product such as formulation, manufacturing process and indications. Additionally, the new patent represents improvements over the original product, including better delivery efficiency, reduced side effects, and sustained-release compounds. These incremental innovations will continue to benefit patients and help advance the medical field.
Subsequent gains from innovation have yielded irreplaceable benefits to people around the world. Consider Botox, which was originally approved as a treatment for eye disease. There are currently over 11 approved treatments, including cerebral palsy. Similarly, AZT was originally developed for the treatment of cancer, but after years of unsuccessful regulatory submissions and heavy investment in clinical trials and research, it became a potential life-saving treatment for HIV/AIDS. gender was discovered. These examples highlight the importance of continuing to invest in research and development made possible by a strong patent system.
accept the fact
The examples above are just a few of the many examples of the effectiveness of a strong patent protection system. Maintaining a healthy patent environment is essential if we are to continue moving toward our common goal of life-saving innovation. Instead of promoting false political narratives, legislators should embrace the facts and recognize that a robust patent system is in everyone’s best interest. By doing so, patients will have access to new treatments and America will continue to lead the world. Are there any alternatives we should really consider?
Image Source: Deposit Photo
Image ID: 6496641
Author: Stuart Miles
